We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Gilead Sciences Inc | NASDAQ:GILD | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.23 | 0.35% | 65.50 | 65.49 | 66.13 | 66.3507 | 64.63 | 65.50 | 12,382,427 | 01:00:00 |
From Apr 2019 to Apr 2024
By Stephen Nakrosis
Gilead Sciences Inc. and Galapagos NV on Wednesday said results from a trial of their filgotinib 200 mg in adult patients with moderately to severely active ulcerative colitis showed it had "achieved all primary endpoints in the study, inducing clinical remission at Week 10 and maintaining clinical remission at Week 58 in a significantly higher proportion of patients compared with placebo."
The companies said the Phase 2b/3 Selection trial evaluated "the efficacy and safety of the investigational, oral, once-daily, selective JAK1 inhibitor filgotinib in 1,348 biologic-naïve or biologic-experienced adult patients with moderately to severely active ulcerative colitis."
The companies also said filgotinib 100 mg didn't achieve statistically significant clinical remission at Week 10.
Detailed results from the trial will be submitted for presentation at a future scientific conference, the companies said.
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
May 20, 2020 16:53 ET (20:53 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Gilead Sciences Chart |
1 Month Gilead Sciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
